Report of Foreign Issuer (6-k)
27 Juillet 2020 - 10:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2020.
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrants name into English)
136a Eastern
Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On July 27, 2020, Summit Therapeutics plc (the Company) announced that it is convening a
court meeting of shareholders (the Court Meeting) and a general meeting of shareholders (the General Meeting and together with the Court Meeting, the Meetings) to be held at 1:30 p.m. BST and 1:40 p.m. BST,
respectively, on August 19, 2020 in connection with the Companys proposed change of corporate domicile to the United States, to be effected by a United Kingdom court-approved scheme of arrangement (the Scheme), and to consider
and, if thought fit, pass resolutions to, inter alia, approve the implementation of the Scheme, a reduction of capital of the Company, certain amendments to the Companys articles of association and the 2020 Stock Incentive Plan and the 2020
Employee Stock Purchase Plan of Summit Therapeutics Inc., a Delaware corporation that will be the new U.S. holding company following effectiveness of the Scheme, if approved by shareholders and subsequently sanctioned by the Court. The Scheme is
expected to become effective on September 18, 2020.
The circular, including notices convening the Meetings, that will be sent to the Companys
shareholders is attached as Exhibit 99.1 to this Form 6-K and is incorporated herein by reference.
This Report on
Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statement on Form F-3 (File
No. 333-232074).
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Scheme Circular and Notices of Meetings, dated July 27, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUMMIT THERAPEUTICS PLC
|
|
|
|
|
Date: July 27, 2020
|
|
|
|
By:
|
|
/s/ Robert W. Duggan
|
|
|
|
|
|
|
Robert W. Duggan
|
|
|
|
|
|
|
Chief Executive Officer
|
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024